# Clinical Trials Data ALK - Document 17

# Analysis of Plasma Tumor DNA in Lung Cancer Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01930474

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer\n\* Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)\n\* Patients must have given written informed consent\n\nExclusion Criteria:\n\n\* Patients who refuse the blood samplings",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "The non-small cell lung cancer patients who will be or have been treated with chemotherapy (including target agents)",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with an ALK gene mutation would be eligible for the clinical trial. The inclusion criteria specifically mention that the patient should have molecular evidence of genetic alterations in the tumor sample, such as ALK fusions. Since the patient has an ALK gene mutation, they meet this part of the inclusion criteria. As long as they meet the other inclusion criteria and do not meet any exclusion criteria (such as refusing blood samplings), they would be eligible to participate in the trial.